Cognitive & Nootropic

Bromantane

Ladasten · bromantan · N-(2-adamantyl)-N-(para-bromophenyl)amine

Adamantane-derived actoprotector (Ladasten in Russia). Small molecule — not a peptide, not Noopept, not Semax. Russian neurasthenia/asthenia clinical files exist; not an FDA cognition NDA.

Not FDA-approved - research chemical
Reviewed by CalcMyPeptide Editorial Team
Last updated: September 2026Evidence: Low3 peer-reviewed citations
Typical research dose
Russian product / study context - not a US NDA
Frequency
Oral courses in Russian clinical tradition (not a US label)
Half-life
Hours-class; adipose depot prolongs detection (review-level PK)
Common vials
N/A (oral)
CAS
87913-26-6
Molecular weight
~306.2 g/mol

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

  • Cognition3/10

    Russian clinical abstracts for neurasthenia/asthenia plus actoprotector pharmacology reviews. Ceiling after haircut for single-tradition human work and no US NDA: 3.

Compound card

Sequence
N-(2-adamantyl)-N-(para-bromophenyl)amine (not a peptide)
Class
Oral actoprotector / atypical stimulant-anxiolytic (Russian Ladasten lineage)
Formula
C16H20BrN
Status
Not FDA-approved · research use

How it works

Bromantane is an adamantane small molecule (Ladasten in Russia), not a lyophilized peptide. Oliynyk and Oh (J Lifestyle Med / PMC3762282) summarize it among actoprotectors: oral bioavailability about 42%, high lipophilicity with adipose deposition, dopaminergic activation without classical stimulant hyperstimulation, plus GABA-ergic and immunomodulatory claims from the Morozov/Seredenin tradition.

English and Russian-line sources commonly describe enhanced dopamine synthesis via tyrosine hydroxylase upregulation rather than amphetamine-like monoamine release. Treat first-receptor claims as incompletely settled in opened reviews.

It is not Noopept, not Semax, not Selank, and not a SubQ reconstitution job.

Source: Opened actoprotector review (Oliynyk & Oh 2012) and PubMed ladasten clinical abstracts; Russian product history is not a US label

Goal context

Actoprotector identity, not a Western stimulant NDA

Ladasten product history in Russia for asthenic syndromes is real. It is not FDA-approved for ADHD, depression, or “study drugs,” and it is not a peptide cake.

Noopept co-use — anecdote

Forum stacks pair bromantane with Noopept. We opened no co-administration RCT. See the bromantane essay and the Noopept leaf. Label the pair as anecdote.

Research Use Cases

  • ✓Actoprotector identity, not a Western stimulant NDA
  • ✓Noopept co-use — anecdote

Dosing

PhaseDoseFrequencyNotes
Opened clinical tradition (abstract-level)Per Russian Ladasten labeling / full papers — not copied here as a DIY chartMulti-week oral courses in neurasthenia study designsWe opened abstracts and a pharmacology review. We are not republishing a milligram protocol from secondary wiki summaries as medical advice.
Community oral folkloreProduct-dependentDaily oral in logsConfirm the product you actually have. Research powders ≠ Ladasten tablets.

Administration

Route / form
Oral (product forms). Not a default lyophilized SubQ peptide.
Timing
Daytime in community practice
Empty stomach?
No - Food timing is not critical.

Timeline

Days (anecdote / Russian course narratives)
Asthenia symptom movement described across multi-week courses in opened abstracts — not an instant stimulant hit for everyone.

Who it is for

Actoprotector / nootropic identity literacy

Moderate

Useful leaf to stop 404s from Noopept stack mentions.

US prescription care for diagnosed disease

Low

Not a US NDA substitute.

Safety & Considerations

Opened reviews describe low addictive framing relative to classical stimulants at therapeutic traditions, but CNS stimulation can still disturb sleep, mood, and blood pressure. Research powders have unknown purity. Not for pregnancy. Check sport anti-doping lists if you compete.

Regulatory & Legal Status

FDA Status (US)
Research Only

Not an FDA-approved US cognition/fatigue drug; Russian Ladasten history is not a US NDA

WADA Status (2026)
Monitoring

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

  • Not an FDA-approved cognition or fatigue drug in the United States.
  • Not a peptide. No BAC-water reconstitution chart.
  • Not Semax, Selank, or Noopept.
  • Opened human work is largely single-tradition / abstract-accessible; not a Western Phase 3 program.
  • Noopept co-administration remains anecdote without an opened combo RCT.
  • This site will not treat ADHD, anxiety, or depression from a bromantane page.

Human evidence

Limited · Russian clinical tradition (not a US cognition NDA)

  • Neznamov et al. (PubMed PMID 19491814): randomized blind ladasten vs placebo in neurasthenia; 28-day monotherapy window in the design; abstract reports superior reduction of asthenic symptoms vs placebo and no withdrawal syndrome after stopping.
  • Syunyakov / Neznamov / Seredenin pilot (PubMed PMID 16995430): pilot clinical trial describing combined stimulant and anxiolytic-like effects in psychogenic asthenic disorder.
  • Oliynyk & Oh actoprotector review (PMC3762282): pharmacology synthesis including ~42% oral bioavailability and dopaminergic framing.
  • This site will not treat ADHD, anxiety disorders, or depression from a bromantane page.

User reports

What community logs claim

Users describe smoother stimulation than classical stimulants, with milder anxiety tradeoffs — or nothing at all. Headache, irritability, and insomnia appear in logs when doses climb. None of that is a counted RCT endpoint here.

Noopept stacks — anecdote only

Study-stack folklore pairs bromantane with Noopept. No opened combo trial. Do not read synergy into two separate Russian-line marketing stories.

Verdict

Bromantane is a Russian adamantane actoprotector (Ladasten) with real abstract-level clinical files and a coherent pharmacology review trail. It is not a peptide, not Noopept, and not an FDA cognition drug. Milligram schedules belong to Russian labeling and full papers — not a DIY US protocol on this leaf.

Interactions & Contraindications

Opened reviews describe low addictive framing relative to classical stimulants at therapeutic traditions, but CNS stimulation can still disturb sleep, mood, and blood pressure. Research powders have unknown purity. Not for pregnancy. Check sport anti-doping lists if you compete.

Frequently Asked Questions

Is bromantane a peptide?▼
No. It is an adamantane small-molecule actoprotector.
Is it the same as Noopept?▼
No. Noopept is a dipeptide ester nootropic. Bromantane is Ladasten-class. Different molecules.
Is it FDA-approved?▼
Not for US cognition or fatigue indications on this leaf. Russian Ladasten history is not an FDA label.
Can I stack it with Noopept?▼
Forum practice exists. We opened no combination trial. Label it anecdote. See /blog/bromantane-ladasten-guide.

References

  1. Oliynyk S, Oh S. “The Pharmacology of Actoprotectors.” J Lifestyle Med (2012). PMID: 24031118
  2. Neznamov GG, et al. “Ladasten in neurasthenia (placebo-comparative clinical study).” Zh Nevrol Psikhiatr (PubMed abstract) (2009). PMID: 19491814
  3. Syunyakov SA, et al. “Pilot clinical trial of ladasten.” Zh Nevrol Psikhiatr (PubMed abstract) (2006). PMID: 16995430

📚 Related Articles

Bromantane (Ladasten): Russian Actoprotector Identity, Mechanism, and Noopept Stack Folklore
11 min read • Cognitive
Semax vs Selank: The Ultimate Nootropic Guide & Stacking Protocol
12 min read • Education

Looking for a trusted source? See our recommended suppliers

Independently tested · COA-verified · Save 10% with our exclusive code

See suppliers →
← Back to Peptide Library